Sumitomo Pharma Co Stock Net Income
| SMDPY Stock | 11.45 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Sumitomo Pharma's long-term financial health and intrinsic value.
Sumitomo |
Sumitomo Pharma Co Company Net Income Analysis
Sumitomo Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Sumitomo Pharma Net Income | 56.41 B |
Most of Sumitomo Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sumitomo Pharma Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Sumitomo Pharma Co reported net income of 56.41 B. This is much higher than that of the sector and significantly higher than that of the Net Income industry. The net income for all United States stocks is notably lower than that of the firm.
Sumitomo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sumitomo Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sumitomo Pharma could also be used in its relative valuation, which is a method of valuing Sumitomo Pharma by comparing valuation metrics of similar companies.Sumitomo Pharma is currently under evaluation in net income category among its peers.
Sumitomo Fundamentals
| Return On Equity | -0.0068 | |||
| Return On Asset | 0.0178 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 2.85 B | |||
| Shares Outstanding | 397.29 M | |||
| Shares Owned By Institutions | 0.10 % | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 560.03 B | |||
| Gross Profit | 402.91 B | |||
| EBITDA | 124.36 B | |||
| Net Income | 56.41 B | |||
| Total Debt | 243.96 B | |||
| Book Value Per Share | 1,626 X | |||
| Cash Flow From Operations | 31.24 B | |||
| Earnings Per Share | 0.24 X | |||
| Number Of Employees | 6.99 K | |||
| Beta | 0.36 | |||
| Market Capitalization | 3.05 B | |||
| Total Asset | 1.31 T | |||
| Net Asset | 1.31 T | |||
| Last Dividend Paid | 28.0 |
About Sumitomo Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sumitomo Pharma Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sumitomo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sumitomo Pharma Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sumitomo Pink Sheet Analysis
When running Sumitomo Pharma's price analysis, check to measure Sumitomo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sumitomo Pharma is operating at the current time. Most of Sumitomo Pharma's value examination focuses on studying past and present price action to predict the probability of Sumitomo Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sumitomo Pharma's price. Additionally, you may evaluate how the addition of Sumitomo Pharma to your portfolios can decrease your overall portfolio volatility.